News

• FDA accepts Alzheimer drug for traditional approval path
  03/06/2023 / 05:18 - TeleTrader
•  
• FDA approves drug for early Alzheimer's treatment
  01/06/2023 / 21:10 - TeleTrader
•  
• Wall Street extends losses on rate talks, China unrest
  11/28/2022 / 19:15 - TeleTrader
•  
• Biogen falls 5% after death in Alzheimer's drug trial
  11/28/2022 / 13:40 - TeleTrader
•  
• Biogen's EPS sees annual jump of 253% in Q3
  10/25/2022 / 13:05 - TeleTrader
•  
• Biogen's Q2 EPS soar by 142.14% to $7.24 per share
  07/20/2022 / 13:01 - TeleTrader
•  
• Biogen revenue slips 6% to $2.53B in Q1
  05/03/2022 / 13:09 - TeleTrader
•  
• Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
  03/28/2022 / 13:30 - GlobeNewswire
•  
• Biogen Announces Peer-Reviewed Publication of ADUHELM® Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer’s Disease
  03/16/2022 / 16:54 - GlobeNewswire
•  
• Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments
  03/15/2022 / 00:00 - GlobeNewswire
•  
• Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference
  03/14/2022 / 12:30 - GlobeNewswire
•  
• Biogen to Present New Research at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2022)
  03/11/2022 / 22:30 - GlobeNewswire
•  
• Frontier Medicines Announces the Appointment of Monique Bobadilla as Chief People and Culture Officer
  03/08/2022 / 14:00 - GlobeNewswire
•  
• Candel Therapeutics Appoints Seshu Tyagarajan, Ph.D., RAC, as Chief Technical and Development Officer
  03/02/2022 / 14:00 - GlobeNewswire
•  
• Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA® (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis
  02/07/2022 / 22:05 - GlobeNewswire